OBIO Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
88.0K
-20.0%
110.0K
-99.6%
30.9M
+3490.8%
861.0K
+3.0%
836.0K
Cost of Revenue
25.0K
-21.9%
32.0K
-37.3%
51.0K
+4.1%
49.0K
+6.5%
46.0K
Gross Profit
63.0K
-19.2%
78.0K
-99.7%
30.9M
+3701.2%
812.0K
+2.8%
790.0K
Operating Expenses
22.4M
+1.2%
22.2M
-8.1%
24.1M
+14.1%
21.1M
+5.0%
20.1M
R&D
16.6M
+5.1%
15.8M
-6.2%
16.8M
+19.9%
14.0M
+1.3%
13.9M
SG&A
5.8M
-8.5%
6.4M
-12.6%
7.3M
+2.7%
7.1M
+13.3%
6.3M
Operating Income
-22356000
-1.3%
-22076000
-426.9%
6.8M
+133.2%
-20313000
-5.1%
-19327000
EBITDA
-22260000
-1.2%
-21986000
-421.6%
6.8M
+133.8%
-20232000
-5.1%
-19246000
Net Income
-23755000
-14.8%
-20691000
-431.3%
6.2M
+130.0%
-20828000
-7.6%
-19363000
EPS (Basic)
$-0.38
-15.2%
$-0.33
-430.0%
$0.10
+125.0%
$-0.40
+20.0%
$-0.50
EPS (Diluted)
$-0.38
-15.2%
$-0.33
-430.0%
$0.10
+125.0%
$-0.40
+20.0%
$-0.50
Shares (Diluted)
63.8M
+1.7%
62.7M
+0.9%
62.2M
+19.1%
52.2M
+35.9%
38.4M
Orchestra BioMed (OBIO) โ€” Financials